PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
PTC Therapeutics (PTCT) Tops Q2 EPS by 14c
July 29, 2021 4:01 PM EDTPTC Therapeutics (NASDAQ: PTCT) reported Q2 EPS of ($1.68), $0.14 better than the analyst estimate of ($1.82). Revenue for the quarter came in at $116.7 million versus the consensus estimate of $110.5 million.
For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.
... More